Mindray Medical International (NYSE: MR) reported earnings on Nov. 5. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Mindray Medical International missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share contracted.

Gross margins expanded, operating margins dropped, net margins dropped.

Revenue details
Mindray Medical International logged revenue of $257.1 million. The six analysts polled by S&P Capital IQ hoped for sales of $266.1 million on the same basis. GAAP reported sales were 18% higher than the prior-year quarter's $218.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.42. The five earnings estimates compiled by S&P Capital IQ predicted $0.45 per share. GAAP EPS of $0.30 for Q3 were 3.2% lower than the prior-year quarter's $0.31 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 56.0%, 110 basis points better than the prior-year quarter. Operating margin was 15.2%, 250 basis points worse than the prior-year quarter. Net margin was 13.9%, 320 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $310.4 million. On the bottom line, the average EPS estimate is $0.54.

Next year's average estimate for revenue is $1.06 billion. The average EPS estimate is $1.81.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,353 members out of 1,388 rating the stock outperform, and 35 members rating it underperform. Among 282 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 268 give Mindray Medical International a green thumbs-up, and 14 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $35.51.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Mindray Medical International Limited. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.